An open-label, single arm, phase 2 study of rituximab, gemcitabine, and oxaliplatin plus enzastaurin as treatment for patients with relapsed diffuse large B-cell lymphoma.

Trial Profile

An open-label, single arm, phase 2 study of rituximab, gemcitabine, and oxaliplatin plus enzastaurin as treatment for patients with relapsed diffuse large B-cell lymphoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Nov 2012

At a glance

  • Drugs Enzastaurin; Gemcitabine; Oxaliplatin; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Dec 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 03 Mar 2007 Status changed from initiated.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top